Table 1 p65BTK score of the NSCLC patients’ tissue analyzed by IHC
From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
p65BTK expression | All (382) | AdC (293) | SCC (89) | Smokers (283) | Non-smokers (65) |
|---|---|---|---|---|---|
Negative | 189 (49.3%) | 129 (43.9%) | 60 (67.4%) | 151 (53.3%) | 18 (27.7%) |
1–10% positive cells | 131 (34.2%) | 106 (36%) | 25 (28.1%) | 101 (35.7%) | 21 (32.3%) |
11–20% positive cells | 12 (3.1%) | 10 (3.4%) | 2 (2.2%) | 5 (1.8%) | 5 (7.7%) |
21–50% positive cells | 24 (6.3%) | 23 (7.8%) | 1 (1.1%) | 15 (5.3%) | 8 (12.1%) |
51–100% positive cells | 26 (6.8%) | 25 (8.5%) | 1 (1.1%) | 11 (3.9%) | 13 (20%) |
Positive | 193(50.4%) | 164 (55.8%) | 29 (32.6%) | 132 (46.7%) | 47 (72.3%) |